Durand-Zaleski I - Search Results

1

[Cost-effectiveness of lung volume reduction coil treatment in emphysema. STIC REVOLENS].

Deslee G, Barbe C, Bourdin A, Durand-Zaleski I, Dutau H, Jolly D, Jounieaux V, Kessler R, Mal H, Pison C, Thiberville L, Vergnon JM, Marquette CH. Deslee G, et al. Rev Mal Respir. 2012 Nov;29(9):1157-64. doi: 10.1016/j.rmr.2012.09.010. Epub 2012 Oct 12. Rev Mal Respir. 2012. PMID: 23200592 Clinical Trial. French.

2

[Economic burden of COPD: the SCOPE study].

Fournier M, Tonnel AB, Housset B, Huchon G, Godard P, Vervloet D, Huas D, Durand-Zaleski I, Chanal I, Pribil C; Groupe SCOPE. Fournier M, et al. Rev Mal Respir. 2005 Apr;22(2 Pt 1):247-55. doi: 10.1016/s0761-8425(05)85478-6. Rev Mal Respir. 2005. PMID: 16092163 French.

3

Technology assessment in health care--decision makers and health care providers: what they need to know.

Durand-Zaleski I, Jolly D. Durand-Zaleski I, et al. Health Policy. 1990;15(1):37-44. doi: 10.1016/0168-8510(90)90416-b. Health Policy. 1990. PMID: 10106860 Review.

4

High technology in health care.

Durand-Zaleski I, Jolly D. Durand-Zaleski I, et al. Qual Assur Health Care. 1990;2(3-4):321-7. doi: 10.1093/intqhc/2.3-4.321. Qual Assur Health Care. 1990. PMID: 1983252

5

[Evaluation of quality of care in the United States].

Durand-Zaleski I, Audet AM, Greenfield S, Jolly D. Durand-Zaleski I, et al. Rev Epidemiol Sante Publique. 1991;39(5):467-76. Rev Epidemiol Sante Publique. 1991. PMID: 1775700 French.

6

[Prevention of COPD exacerbation: a fundamental challenge].

Roche N, Aguilaniu B, Burgel PR, Durand-Zaleski I, Dusser D, Escamilla R, Perez T, Raherison C, Similowski T; groupe d’expert « Exacerbations de BPCO ». Roche N, et al. Rev Mal Respir. 2012 Jun;29(6):756-74. doi: 10.1016/j.rmr.2012.04.006. Epub 2012 Jun 6. Rev Mal Respir. 2012. PMID: 22742463 Review. French.

7

Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues.

Chaix-Couturier C, Durand-Zaleski I, Jolly D, Durieux P. Chaix-Couturier C, et al. Int J Qual Health Care. 2000 Apr;12(2):133-42. doi: 10.1093/intqhc/12.2.133. Int J Qual Health Care. 2000. PMID: 10830670 Review.

8

Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.

Montagne O, Vedel I, Durand-Zaleski I. Montagne O, et al. Clin Ther. 1999 Nov;21(11):2027-35. doi: 10.1016/S0149-2918(00)86748-X. Clin Ther. 1999. PMID: 10890271

9

Infection risk and cost-effectiveness of commercial bags or glass bottles for total parenteral nutrition.

Durand-Zaleski I, Delaunay L, Langeron O, Belda E, Astier A, Brun-Buisson C. Durand-Zaleski I, et al. Infect Control Hosp Epidemiol. 1997 Mar;18(3):183-8. doi: 10.1086/647584. Infect Control Hosp Epidemiol. 1997. PMID: 9090546

10

Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome.

Espérou H, Jars-Guincestre MC, Bolgert F, Raphaël JC, Durand-Zaleski I. Espérou H, et al. Intensive Care Med. 2000 Aug;26(8):1094-100. doi: 10.1007/s001340051323. Intensive Care Med. 2000. PMID: 11030166 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

397 results

Search Page

Filters